Condition
Contraception
ClinicalTrials.gov condition label
Clinical trials
60 shownPharmacokinetic Study of Long-acting Antiretrovirals and Contraceptives in HIVNCT07516548 · 2025-01-24
RECRUITINGPharmacokinetics of Drospirenone Only Pills: A Pre- and Post-Bariatric Surgery StudyNCT06345560 · 2024-04-18
RECRUITINGDrospirenone Only Pills and Cervical Mucus Changes: A Pre- and Post-Bariatric Surgery StudyNCT06345586 · 2024-04-18
RECRUITINGKuwa Free! - Live Free!NCT05044962 · 2021-11-26
RECRUITINGDYnamic decisioN Support for IntegrAting PrEP in Clinics for Young People in Alabama and BotswanaNCT07597824 · 2026-10-01
NOT_YET_RECRUITINGExploring Reproductive Health Among Women in SomalilandNCT07438379 · 2025-01-01
ENROLLING_BY_INVITATIONA Crossover Acceptability Study Assessing a DPP Capsule for HIV and Pregnancy PreventionNCT04778514 · 2022-12-07
COMPLETEDMobile Phone Messaging to Improve Reproductive Health for Women Living With HIV in Kenya (Mobile WACh Empower)NCT05285670 · 2022-12-01
ACTIVE_NOT_RECRUITINGSupporting Young Women's Reproductive Health by Harnessing Prosociality Among Drug ShopkeepersNCT05525533 · 2022-07-01
TERMINATEDEvaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South AfricaNCT04669678 · 2021-11-17
COMPLETEDInvestigating the Interaction Between Two Long-acting Reversible Methods of Contraception and Dolutegravir, a Treatment for HIVNCT04910711 · 2021-10-21
UNKNOWNIntervening on Women's Health for Rural Young Breast Cancer SurvivorsNCT05414812 · 2021-10-15
COMPLETEDPrEParing Family Planning Clinics to Streamline Integration of HIV Prevention Services for Young Women in KenyaNCT04666792 · 2021-03-01
COMPLETEDContraception and Pregnancy in Diabetes MellitusNCT04523454 · 2020-10-02
COMPLETEDBreast Cancer and Intrauterine ContraceptionNCT05148910 · 2020-08-06
UNKNOWNSexual and Reproductive Health (Including PrEP and HBV) for Female Sex Workers in Côte d'IvoireNCT03985085 · 2019-11-26
UNKNOWNReaching Adolescent Girls and Young Women Through Girl-Friendly Drug VendorsNCT04045912 · 2019-07-22
COMPLETEDPharmacologic Strategies for the Etonogestrel Implant in HIV-Infected WomenNCT03282799 · 2019-02-19
COMPLETEDTenofovir/Levonorgestrel Intravaginal Ring and Tenofovir Intravaginal RingNCT03762382 · 2018-12-12
UNKNOWNDarunavir and Rilpivirine Interactions With Etonogestrel Contraceptive ImplantNCT03589040 · 2018-09-25
UNKNOWNCounseling on Injectable Contraception and HIV Risk in TanzaniaNCT04160169 · 2018-09-01
COMPLETEDDarunavir and Rilpivirine Interactions With Levonorgestrel ImplantNCT03589027 · 2018-08-07
UNKNOWNPK Study of 90-Day Use of Vaginal Rings Containing Dapivirine and LevonorgestrelNCT03467347 · 2018-07-17
COMPLETEDPharmacokinetics and Pharmacodynamics of DMPA With HIV PrEPNCT03197961 · 2017-11-17
COMPLETEDModifiers of Tenofovir in the Female Genital TractNCT03377608 · 2017-11-17
COMPLETEDContraceptive/HIV Affecting Risk in AdolescentsNCT03301480 · 2017-07-31
TERMINATEDEffectiveness of Orally Dosed Emergency Contraception in Obese Women - UPANCT02859337 · 2017-05-30
COMPLETEDPharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected WomenNCT02722421 · 2017-04-06
COMPLETEDCompare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell ProliferationNCT02922127 · 2016-12-16
COMPLETEDHigh-risk Obstetrical Patient Intervention Utilizing the Contraceptive CHOICE Project ScriptNCT03049592 · 2016-07-01
COMPLETEDThe Quatro Study: Acceptability Study of (Placebo) Vaginal Delivery Forms for Preventing HIV and Unintended PregnancyNCT02602366 · 2016-06-06
COMPLETEDThe Evidence for Contraceptive Options and HIV Outcomes TrialNCT02550067 · 2015-12-14
COMPLETEDProtease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and PharmacodynamicsNCT02531321 · 2015-08-01
TERMINATEDEC PK in Women With Normal and Obese BMINCT02689804 · 2015-07-10
COMPLETEDReproductive Health Survivorship Care PlanNCT02667626 · 2015-03-25
COMPLETEDImpact of Hormonal Contraception on HIV Acquisition and Transmission RiskNCT02357368 · 2015-02-01
COMPLETEDEmergency Contraception and Body Weight: Pilot StudyNCT02408692 · 2015-02-01
COMPLETEDA Pharmacokinetic Evaluation of Etonogestrel (ENG) Implant and Antiretroviral TherapyNCT02082652 · 2014-10-01
COMPLETEDPhase I One-month Safety, PK, PD, and Acceptability Study of IVR Releasing TFV and LNG or TFV AloneNCT02235662 · 2014-10-01
COMPLETEDClinical Trial on the Effects of Progestin-based Contraception in the Genital Tract of HIV-infected and Uninfected WomenNCT02103660 · 2014-04-08
COMPLETEDA Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral TherapyNCT01789879 · 2014-03-04
COMPLETEDThe Effect of Early Versus Traditional Follow-Up on Breastfeeding Rates at 6 MonthsNCT02221895 · 2014-03-01
COMPLETEDHIV-Target Cell Response in Women Initiating Various Contraceptive Methods in High HIV-Incidence Areas: Zim CHICNCT02038335 · 2014-02-01
COMPLETEDQuantification of Immune Cells in Women Using Contraception (CHIC II)NCT01873170 · 2013-08-01
COMPLETEDObesity and Oral Contraceptive FailureNCT01944306 · 2013-08-01
TERMINATEDEvaluation of a Peer Education Program to Promote Family Planning Among Female Sex Workers in KenyaNCT01957813 · 2013-06-20
COMPLETEDFamily Planning Knowledge, Attitudes, and Practices of Postpartum Malawian WomenNCT01893021 · 2013-05-01
COMPLETEDThe Effect of Body Mass Index on Etonogestrel Hormone Levels in Women Using the Single-rod Contraceptive ImplantNCT01855620 · 2012-12-01
COMPLETEDMobile Phone Text Messaging ReferralNCT01746758 · 2012-08-01
UNKNOWNChoices-Teen: A Bundled Risk Reduction Intervention for Juvenile Justice FemalesNCT02252471 · 2012-07-01
COMPLETEDAcceptability of Depo-subQ in UnijectNCT01667276 · 2012-07-01
COMPLETEDA Prospective Observational Study of the Clinical Performance of Femplant in PakistanNCT01463254 · 2011-10-01
COMPLETEDEnhancing Uptake of Family Planning Services by HIV-Infected Women Attending the PMTCT ProgramNCT03019601 · 2011-09-01
COMPLETEDSafety,Effectiveness and Acceptability of Sino-implant II in DRNCT01594632 · 2011-01-01
COMPLETEDUS Ovulation Inhibition Study in Obese WomenNCT00873483 · 2009-04-30
COMPLETEDImpact of Different Contraceptives on the Immune System of HIV Infected Women in ZambiaNCT00807625 · 2008-11-01
COMPLETEDPharmacokinetics of Implanon in Obese WomenNCT00724438 · 2008-07-01
COMPLETEDAssessing Preference for 3 Female Condoms: A Comparative Evaluation of the PATH Woman's Condom, FC2 and the Reddy 6NCT01452503 · 2007-05-01
COMPLETEDA Study of the Drug Interactions Between a Hormonal Emergency Contraception and an HIV MedicationNCT00482963 · 2007-05-01
COMPLETEDOral Contraceptive Efficacy and Body WeightNCT00662454 · 2006-01-01
COMPLETEDCommon interventions
DMPADRUG3LevonorgestrelDRUG3DrospirenoneDRUG2EfavirenzDRUG2Etonogestrel (ETG) implantDRUG2Intramuscular depo-medroxyprogesterone acetate (IM DMPA)DRUG2RilpivirineDRUG2TFV IVRDRUG2TFV/LNG IVRDRUG2AGYW-Friendly ServicesOTHER1Cabotegravir/ RilpivirineDRUG1Choices-TeenBEHAVIORAL1Combined Oral Contraceptive PillDRUG1Comprehensive package of sexual and reproductive health servicesOTHER1ControlOTHER1Copper IUDDRUG1Copper IUD (TCu380A)DEVICE1Copper T Intrauterine contraception deviceDEVICE1Counseling messages on injectable use and HIV acquisition riskOTHER1Cu-IUDDEVICE1darunavirDRUG1Darunavir+RitonavirDRUG1Depo medroxyprogesterone acetate injectionDRUG1Depo ProveraDRUG1Depo-Medroxyprogesterone AcetateDRUG1
Leading sponsors
FHI 3606University of Alabama at Birmingham5Oregon Health and Science University4University of Pittsburgh4Columbia University3CONRAD3University of California, San Diego3Chulalongkorn University2Makerere University2University of California, San Francisco2University of Nebraska2University of North Carolina, Chapel Hill2University of Washington2ANRS, Emerging Infectious Diseases1Bayer1
Trial status mix
COMPLETED42
UNKNOWN7
RECRUITING4
TERMINATED4
ACTIVE_NOT_RECRUITING1
ENROLLING_BY_INVITATION1
NOT_YET_RECRUITING1
Phase mix
NA20
PHASE411
PHASE29
PHASE15
EARLY_PHASE11
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.